Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing
Authors:
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Experimental Hematology
- Vol. 92, 51-61
Abstract
No abstract availableKeywords
Funding Information
- Spectrum Pharmaceuticals
This publication has 21 references indexed in Scilit:
- Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating FactorBioDrugs, 2015
- IgG Subclasses and Allotypes: From Structure to Effector FunctionsFrontiers in Immunology, 2014
- G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agentCytokine & Growth Factor Reviews, 2014
- The Immunologic Functions of the Neonatal Fc Receptor for IgGJournal of Clinical Immunology, 2012
- Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non–Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II StudiesJournal of Oncology Practice, 2010
- Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony‐stimulating factor derivative Maxy‐G34 and pegfilgrastim in ratsCell Proliferation, 2009
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- Chemotherapy‐induced neutropeniaCancer, 2004
- Filgrastim (r-metHuG-CSF) in the 21st Century: SD/01Acta Haematologica, 2001
- CHEMOTHERAPY AND NEUTROPENIAHematology/Oncology Clinics of North America, 1996